metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-31 METHOTREXATE SEEMS NOT TO BE ASSOCIATED WITH LIVER FIBROSIS IN RHEUMATOID A...
Journal Information
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Full text access
P-31 METHOTREXATE SEEMS NOT TO BE ASSOCIATED WITH LIVER FIBROSIS IN RHEUMATOID ARTHRITIS PATIENTS
Visits
141
Leandro Augusto De Araújo1, Maria Fernanda Brandão De Resende1, Mateus Jorge1, Guilherme Grossi2, Sabrina Da Siva1, Kassia Burini1, Mateus Saraiva1, Thais Galdino1, Danilo Rodrigues1, Daniela Oliveira De Lima1, Claudia Alves1, Adriana Maria1, Luciana Costa1
1 Clínica Médica, Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, Brasil
2 Instituto Alfa De Gastroenterologia, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brasil
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 29. Issue S1

Abstracts of the 2023 Annual Meeting of the ALEH

More info
Introduction and Objectives

Methotrexate (MTX) is the first-line treatment for rheumatoid arthritis (RA). Long-term usage of MTX may lead to liver injury, including the development of progressive liver fibrosis. Nevertheless, the prevalence of this adverse event and its associated risk factors remains unclear in RA patients. This study aimed to investigate the risk of long-term MTX therapy on liver fibrosis in patients with RA.

Materials and Methods

A cross-sectional study was conducted among patients with RA recruited from a rheumatology outpatient clinic. Liver fibrosis was assessed using transient elastography. Only patients who had received MTX were included in the study. Patients with a history of alcohol consumption or with known liver diseases were excluded.

Results

A total of 128 patients (91.4% women) with a mean age of 60 ± 12 years were enrolled. The duration of MTX therapy ranged from 3 to 306 months (median 106, interquartile range [IQR] 106). MTX was currently being used by 52% of the patients, with a median cumulative dose of 8022 mg (IQR 9363).

Comorbidities among the participants included diabetes mellitus (21.1%), arterial hypertension (63.3%), dyslipidemia (77.2%), metabolic syndrome (60.3%), and a history of tobacco use (31.3%). The median liver stiffness was 4.9kPa (IQR 2.2). Liver stiffness 8.0kPa was observed in 12.5% of the patients and was found to be associated with a history of tobacco use (p=0.004) and larger waist circumference (p=0.001). Liver stiffness showed a positive correlation with waist circumference (Rho = 0.220, p=0.014), while MTX cumulative dose showed a positive correlation with alanine aminotransferase levels (Rho = 0.250, p=0.005).

Conclusions

12.5% of the patients with RA exposed to long-term MTX therapy exhibited liver stiffness 8kPa. Tobacco use and larger waist circumference were identified as risk factors for liver fibrosis, while MTX cumulative dose was not associated with progressive liver fibrosis.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2023.101194
No mostrar más